Adjuvant Intraperitoneal Floxuridine Added to Chemoradiation for Fully Resected Advanced Stomach Cancer
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
This study is to evaluate the efficacy and safety of addition of intraperitoneal (ip)
Floxuridine to adjuvant chemoradiation therapy for patients under-going potentially curative
stomach resection.
Phase:
Phase 2
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health